Meeting
2019 ASCO Annual Meeting
NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.
Authors
Michaël Duruisseaux
Hospices Civils de Lyon Cancer Institute, Chest Department, Hôpital Louis Pradel, Bron, France
Michaël Duruisseaux , Stephen V. Liu , Ji-Youn Han , Valerie Gounant , Jin-Yuan Shih , Alison M. Schram , Alexa Betzig Schrock , Siraj Mahamed Ali , Fanny Magne , Isabelle Monnet , Denis Moro-Sibilot , Torsten-Gerriet Blum , Tejas Patil , Robert Charles Doebele , D. Ross Camidge , Lucia Anna Muscarella , Jacques Cadranel , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9081)
DOI
10.1200/JCO.2019.37.15_suppl.9081
Abstract #
9081
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2019 ASCO Annual Meeting
Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).
First Author: Zofia Piotrowska
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
First Author: Jeddeo Paul